肿瘤免疫学：破解组合难题。 - Suppr

Suppr

超能文献

Tumour immunology: cracking the combination.

作者信息

Bordon Yvonne

出版信息

Nat Rev Immunol. 2013 Jul;13(7):469. doi: 10.1038/nri3481. Epub 2013 Jun 7.

DOI:10.1038/nri3481

PMID:23743478

Abstract

摘要

相似文献

Tumour immunology: cracking the combination.

Nat Rev Immunol. 2013 Jul;13(7):469. doi: 10.1038/nri3481. Epub 2013 Jun 7.

Anticancer drugs: Cracking the combination.

Nat Rev Drug Discov. 2013 Jul;12(7):505. doi: 10.1038/nrd4071.

Immunology. Making macrophages eat cancer.

Science. 2013 Jul 5;341(6141):41-2. doi: 10.1126/science.1241716.

Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies.

Science. 2013 Jul 5;341(6141):88-91. doi: 10.1126/science.1238856. Epub 2013 May 30.

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors.

J Clin Invest. 2013 Jun;123(6):2447-63. doi: 10.1172/JCI64859.

Targeting immunosuppression for cancer therapy.

J Clin Invest. 2013 Jun;123(6):2355-7. doi: 10.1172/JCI69999.

Inhibitory signaling through signal regulatory protein-α is not sufficient to explain the antitumor activities of CD47 antibodies.

Proc Natl Acad Sci U S A. 2012 Oct 16;109(42):E2842; author reply E2844-5. doi: 10.1073/pnas.1205441109. Epub 2012 Aug 24.

Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors.

Sci Transl Med. 2017 Mar 15;9(381). doi: 10.1126/scitranslmed.aaf2968.

Cancer immunotherapy targeting the CD47/SIRPα axis.

Eur J Cancer. 2017 May;76:100-109. doi: 10.1016/j.ejca.2017.02.013. Epub 2017 Mar 10.

On the mechanism of CD47 targeting in cancer.

Proc Natl Acad Sci U S A. 2012 Oct 16;109(42):E2843; author reply E2844-5. doi: 10.1073/pnas.1209265109. Epub 2012 Aug 24.

引用本文的文献

Dual blockage of both PD-L1 and CD47 enhances the therapeutic effect of oxaliplatin and FOLFOX in CT-26 mice tumor model.

Sci Rep. 2023 Feb 11;13(1):2472. doi: 10.1038/s41598-023-29363-9.

本文引用的文献

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors.

J Clin Invest. 2013 Jun;123(6):2447-63. doi: 10.1172/JCI64859.

Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies.

Science. 2013 Jul 5;341(6141):88-91. doi: 10.1126/science.1238856. Epub 2013 May 30.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Tumour immunology: cracking the combination.

Nat Rev Immunol. 2013 Jul;13(7):469. doi: 10.1038/nri3481. Epub 2013 Jun 7.

Anticancer drugs: Cracking the combination.

Nat Rev Drug Discov. 2013 Jul;12(7):505. doi: 10.1038/nrd4071.

Immunology. Making macrophages eat cancer.

Science. 2013 Jul 5;341(6141):41-2. doi: 10.1126/science.1241716.

Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies.

Science. 2013 Jul 5;341(6141):88-91. doi: 10.1126/science.1238856. Epub 2013 May 30.

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors.

J Clin Invest. 2013 Jun;123(6):2447-63. doi: 10.1172/JCI64859.

Targeting immunosuppression for cancer therapy.

J Clin Invest. 2013 Jun;123(6):2355-7. doi: 10.1172/JCI69999.

Inhibitory signaling through signal regulatory protein-α is not sufficient to explain the antitumor activities of CD47 antibodies.

Proc Natl Acad Sci U S A. 2012 Oct 16;109(42):E2842; author reply E2844-5. doi: 10.1073/pnas.1205441109. Epub 2012 Aug 24.

Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors.

Sci Transl Med. 2017 Mar 15;9(381). doi: 10.1126/scitranslmed.aaf2968.

Cancer immunotherapy targeting the CD47/SIRPα axis.

Eur J Cancer. 2017 May;76:100-109. doi: 10.1016/j.ejca.2017.02.013. Epub 2017 Mar 10.

On the mechanism of CD47 targeting in cancer.

Proc Natl Acad Sci U S A. 2012 Oct 16;109(42):E2843; author reply E2844-5. doi: 10.1073/pnas.1209265109. Epub 2012 Aug 24.

引用本文的文献

Dual blockage of both PD-L1 and CD47 enhances the therapeutic effect of oxaliplatin and FOLFOX in CT-26 mice tumor model.

Sci Rep. 2023 Feb 11;13(1):2472. doi: 10.1038/s41598-023-29363-9.

本文引用的文献

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors.

J Clin Invest. 2013 Jun;123(6):2447-63. doi: 10.1172/JCI64859.

Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies.

Science. 2013 Jul 5;341(6141):88-91. doi: 10.1126/science.1238856. Epub 2013 May 30.